RESUMEN
Background In the Scottish Computed Tomography of the Heart (SCOT-HEART) trial in individuals with stable chest pain, a treatment strategy based on coronary CT angiography (CTA) led to improved outcomes. Purpose To assess 5-year cumulative radiation doses of participants undergoing investigation for suspected angina due to coronary artery disease with or without coronary CTA. Materials and Methods This secondary analysis of the SCOT-HEART trial included data from six of 12 recruiting sites and two of three imaging sites. Participants were recruited between November 18, 2010, and September 24, 2014, with follow-up through January 31, 2018. Study participants had been randomized (at a one-to-one ratio) to standard care with CT (n = 1466) or standard care alone (n = 1428). Imaging was performed on a 64-detector (n = 223) or 320-detector row scanner (n = 1466). Radiation dose from CT (dose-length product), SPECT (injected activity), and invasive coronary angiography (ICA; kerma-area product) was assessed for 5 years after enrollment. Effective dose was calculated using conversion factors appropriate for the imaging modality and body region imaged (using 0.026 mSv/mGy · cm for cardiac CT). Results Cumulative radiation dose was assessed in 2894 participants. Median effective dose was 3.0 mSv (IQR, 2.6-3.3 mSv) for coronary calcium scoring, 4.1 mSv (IQR, 2.6-6.1 mSv) for coronary CTA, 7.4 mSv (IQR, 6.2-8.5 mSv) for SPECT, and 4.1 mSv (IQR, 2.5-6.8 mSv) for ICA. After 5 years, total per-participant cumulative dose was higher in the CT group (median, 8.1 mSv; IQR, 5.5-12.4 mSv) compared with standard-care group (median, 0 mSv; IQR, 0-4.5 mSv; P < .001). In participants who underwent any imaging, cumulative radiation exposure was higher in the CT group (n = 1345; median, 8.6 mSv; IQR, 6.1-13.3 mSv) compared with standard-care group (n = 549; median, 6.4 mSv; IQR, 3.4-9.2 mSv; P < .001). Conclusion In the SCOT-HEART trial, the 5-year cumulative radiation dose from cardiac imaging was higher in the coronary CT angiography group compared with the standard-care group, largely because of the radiation exposure from CT. Clinical trial registration no. NCT01149590 © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Dodd and Bosserdt in this issue.
Asunto(s)
Enfermedad de la Arteria Coronaria , Exposición a la Radiación , Humanos , Dolor en el Pecho/diagnóstico por imagen , Dolor en el Pecho/etiología , Angiografía por Tomografía Computarizada , Angiografía Coronaria/métodos , Enfermedad de la Arteria Coronaria/complicaciones , Enfermedad de la Arteria Coronaria/diagnóstico por imagen , Dosis de Radiación , Tomografía Computarizada por Rayos XRESUMEN
The COVID-19 pandemic is generating great change and challenge to unparalleled levels across the National Health Service, UK. With insufficient and still emerging evidence on this little known virus, recommendations and guidance are changing continually and still evolving. The authors outline some of the planning through the initial stages of the pandemic within a clinical radiology ultrasound service at one UK tertiary centre. Patient triaging, infection control, equipment, staff mental wellbeing, ongoing training and recovery are all subjects of focus. By sharing our experience and strategies, we anticipate that other similar departments may benefit.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Células de la Médula Ósea/patología , Diagnóstico Tardío , Linfoma de Células T Periférico/diagnóstico , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Dolor de Espalda/etiología , Biopsia , Ciclofosfamida/administración & dosificación , Diagnóstico Diferencial , Doxorrubicina/administración & dosificación , Femenino , Fiebre/etiología , Humanos , Cariotipificación , Linfoma de Células T Periférico/complicaciones , Linfoma de Células T Periférico/tratamiento farmacológico , Linfoma de Células T Periférico/patología , Prednisona/administración & dosificación , Vincristina/administración & dosificaciónAsunto(s)
Encéfalo/patología , Cefalea/etiología , Angiografía por Resonancia Magnética/métodos , Vasoespasmo Intracraneal/diagnóstico por imagen , Anciano , Encéfalo/diagnóstico por imagen , Clopidogrel , Femenino , Humanos , Hidroxiurea/uso terapéutico , Ticlopidina/análogos & derivados , Ticlopidina/uso terapéutico , Resultado del Tratamiento , Vasoespasmo Intracraneal/tratamiento farmacológicoRESUMEN
BACKGROUND: Common carotid intima media thickness (CIMT) and ankle brachial pressure index (ABPI) are used as surrogate marker of atherosclerosis, and have been shown to correlate with arterial stiffness, however their correlation with global atherosclerotic burden has not been previously assessed. We compare CIMT and ABPI with atheroma burden as measured by whole body magnetic resonance angiography (WB-MRA). METHODS: 50 patients with symptomatic peripheral arterial disease were recruited. CIMT was measured using ultrasound while rest and exercise ABPI were performed. WB-MRA was performed in a 1.5T MRI scanner using 4 volume acquisitions with a divided dose of intravenous gadolinium gadoterate meglumine (Dotarem, Guerbet, FR). The WB-MRA data was divided into 31 anatomical arterial segments with each scored according to degree of luminal narrowing: 0â=ânormal, 1â=â<50%, 2â=â50-70%, 3â=â70-99%, 4â=âvessel occlusion. The segment scores were summed and from this a standardized atheroma score was calculated. RESULTS: The atherosclerotic burden was high with a standardised atheroma score of 39.5±11. Common CIMT showed a positive correlation with the whole body atheroma score (ß 0.32, pâ=â0.045), however this was due to its strong correlation with the neck and thoracic segments (ß 0.42 pâ=â0.01) with no correlation with the rest of the body. ABPI correlated with the whole body atheroma score (ß -0.39, pâ=â0.012), which was due to a strong correlation with the ilio-femoral vessels with no correlation with the thoracic or neck vessels. On multiple linear regression, no correlation between CIMT and global atheroma burden was present (ß 0.13 pâ=â0.45), while the correlation between ABPI and atheroma burden persisted (ß -0.45 pâ=â0.005). CONCLUSION: ABPI but not CIMT correlates with global atheroma burden as measured by whole body contrast enhanced magnetic resonance angiography in a population with symptomatic peripheral arterial disease. However this is primarily due to a strong correlation with ilio-femoral atheroma burden.
Asunto(s)
Índice Tobillo Braquial , Arteria Carótida Común/ultraestructura , Grosor Intima-Media Carotídeo , Angiografía por Resonancia Magnética/métodos , Enfermedad Arterial Periférica/patología , Placa Aterosclerótica/patología , Imagen de Cuerpo Entero/métodos , Anciano , Biomarcadores , Medios de Contraste , Estudios Transversales , Prueba de Esfuerzo , Femenino , Humanos , Masculino , Meglumina , Persona de Mediana Edad , Compuestos Organometálicos , Método Simple Ciego , Rigidez VascularRESUMEN
BACKGROUND: Rapid access chest pain clinics have facilitated the early diagnosis and treatment of patients with coronary heart disease and angina. Despite this important service provision, coronary heart disease continues to be under-diagnosed and many patients are left untreated and at risk. Recent advances in imaging technology have now led to the widespread use of noninvasive computed tomography, which can be used to measure coronary artery calcium scores and perform coronary angiography in one examination. However, this technology has not been robustly evaluated in its application to the clinic. METHODS/DESIGN: The SCOT-HEART study is an open parallel group prospective multicentre randomized controlled trial of 4,138 patients attending the rapid access chest pain clinic for evaluation of suspected cardiac chest pain. Following clinical consultation, participants will be approached and randomized 1:1 to receive standard care or standard care plus ≥64-multidetector computed tomography coronary angiography and coronary calcium score. Randomization will be conducted using a web-based system to ensure allocation concealment and will incorporate minimization. The primary endpoint of the study will be the proportion of patients diagnosed with angina pectoris secondary to coronary heart disease at 6 weeks. Secondary endpoints will include the assessment of subsequent symptoms, diagnosis, investigation and treatment. In addition, long-term health outcomes, safety endpoints, such as radiation dose, and health economic endpoints will be assessed. Assuming a clinic rate of 27.0% for the diagnosis of angina pectoris due to coronary heart disease, we will need to recruit 2,069 patients per group to detect an absolute increase of 4.0% in the rate of diagnosis at 80% power and a two-sided P value of 0.05. The SCOT-HEART study is currently recruiting participants and expects to report in 2014. DISCUSSION: This is the first study to look at the implementation of computed tomography in the patient care pathway that is outcome focused. This study will have major implications for the management of patients with cardiovascular disease. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01149590.
Asunto(s)
Angina de Pecho/diagnóstico por imagen , Servicio de Cardiología en Hospital , Angiografía Coronaria/métodos , Enfermedad Coronaria/diagnóstico por imagen , Servicio de Urgencia en Hospital , Accesibilidad a los Servicios de Salud , Tomografía Computarizada Multidetector , Proyectos de Investigación , Angina de Pecho/etiología , Angina de Pecho/terapia , Protocolos Clínicos , Enfermedad Coronaria/complicaciones , Enfermedad Coronaria/terapia , Técnicas de Apoyo para la Decisión , Humanos , Valor Predictivo de las Pruebas , Pronóstico , Estudios Prospectivos , Factores de Riesgo , Escocia , Factores de Tiempo , Tiempo de TratamientoRESUMEN
This report describes a technique of inserting an implantable venous access port (portacath) through a thrombosed and occluded vein employing a pre-existing peripherally inserted central catheter (PICC) as the route of access. The PICC was used as a conduit for venous access in a way that has not been described previously in the literature. This procedure was performed in a young patient with cystic fibrosis in an effort to prevent the use of his virgin contralateral veins, which might be used in the future.
Asunto(s)
Cateterismo Venoso Central/métodos , Catéteres de Permanencia , Infusiones Intravenosas/métodos , Trombosis de la Vena/terapia , Adulto , Venas Braquiocefálicas/diagnóstico por imagen , Fibrosis Quística/diagnóstico por imagen , Fibrosis Quística/tratamiento farmacológico , Humanos , Transferasas de Hidroximetilo y Formilo/administración & dosificación , Masculino , Complejos Multienzimáticos/administración & dosificación , Nucleótido Desaminasas/administración & dosificación , Radiografía , Radiología Intervencionista/métodos , Vena Subclavia/diagnóstico por imagen , Ultrasonografía , Grado de Desobstrucción VascularRESUMEN
PURPOSE OF REVIEW: Applications of computed tomography (CT) for cardiac imaging have evolved rapidly with the introduction of new hardware. These advances require a technology update, particularly as the new scanners have novel, unique features. This review focuses on post-64 generation CT scanner capabilities and novel clinical research applications enabled by these technologies. RECENT FINDINGS: By the release date of multicenter publications to evaluate 64-detector row coronary CT, new technology advanced the state of the art in terms of key metrics such as temporal resolution and volume coverage. Moreover, cardiac CT protocols continue to evolve and spark new applications. CT is now being used for plaque detection and is being applied for stress perfusion imaging. In addition, scanners have novel strategies for single heartbeat whole coronary imaging; this has enabled evaluations of endothelial shear stress and differences in coronary contrast opacification at a single point in time. SUMMARY: Continuous improvements in technology have moved CT beyond 64-detector rows. Understanding these technical specifications will enable evaluation of current and future applications for noninvasive cardiac imaging.